Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
11 Maio 2023 - 9:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), announced today its management
team will participate in a fireside chat at the
The JMP Securities Life Sciences Conference on Tuesday, May 16,
2023 at 10:30 am ET.
The fireside chat will be webcast and an archived recording will
be available for replay in the Investors section of the Madrigal
website after the event.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s lead candidate, resmetirom, is a
once daily, oral, thyroid hormone receptor (THR)-β selective
agonist designed to target key underlying causes of NASH in the
liver. For more information, visit www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
